Advertisement

Topics

NEURONAX Will Present the Pre-Clinical Results of Its Lead Product NX210 at Neuroscience 2017

08:00 EST 9 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
NEURONAX, the biopharmaceutical company specializing in neuron protection and regeneration, will present its pre-clinical results highlighting the potential of its lead product NX210 at Neuroscience 2017. Organiz...

Other Sources for this Article

NEURONAX
Yann GODFRIN
Chief Executive Officer
www.neuronax.com
contact@neuronax.com

NEXT ARTICLE

More From BioPortfolio on "NEURONAX Will Present the Pre-Clinical Results of Its Lead Product NX210 at Neuroscience 2017"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Anxiety Disorders
Anxiety is caused by stress. It is a natural reaction, and is beneficial in helping us deal with tense situations and pressure. It is deterimental when is becomes an excessive, irrational dread of everyday situations. The most common types of anxiety di...

Spinal Cord Disorders
The spinal cord is a bundle of nerves that runs down the middle of the back which carry signals back and forth between the body and brain. It is protected by vertebrae, which are the bone disks that make up the spine. An accident that damages the verte...